

**Exhibit A**

**Voluntary Petition for Bankruptcy**

**Fill in this information to identify the case:**

United States Bankruptcy Court for the:

Southern

District of

New York

(State)

Case number (if known):

Chapter

11

☐ Check if this is an amended filing

Official Form 201

**Voluntary Petition for Non-Individuals Filing for Bankruptcy**

06/22

If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor's name and the case number (if known). For more information, a separate document, *Instructions for Bankruptcy Forms for Non-Individuals*, is available.

1. Debtor's name Endo International plc

2. All other names debtor used in the last 8 years Sportwell Limited

Include any assumed names, trade names, and doing business as names

3. Debtor's federal Employer Identification Number (EIN) 68-0683755

4. Debtor's address

Principal place of business

First Floor, Minerva House, Simmons Court Road

Number Street

Ballsbridge

City

Dublin 4 Ireland

State ZIP Code

Mailing address, if different from principal place of business

1400 Atwater Drive

Number Street

P.O. Box

Malvern

City

PA 19355

State ZIP Code

Location of principal assets, if different from principal place of business

County

Number Street

City

State ZIP Code

5. Debtor's website (URL) www.endo.com

Debtor

Endo International plc  
Name

Case number (if known)

**6. Type of debtor**

- ☐ Corporation (including Limited Liability Company (LLC) and Limited Liability Partnership (LLP))  
☐ Partnership (excluding LLP)  
☒ Other. Specify: Public Limited Company

**7. Describe debtor's business**

A. Check one:

- ☐ Health Care Business (as defined in 11 U.S.C. § 101(27A))  
☐ Single Asset Real Estate (as defined in 11 U.S.C. § 101(51B))  
☐ Railroad (as defined in 11 U.S.C. § 101(44))  
☐ Stockbroker (as defined in 11 U.S.C. § 101(53A))  
☐ Commodity Broker (as defined in 11 U.S.C. § 101(6))  
☐ Clearing Bank (as defined in 11 U.S.C. § 781(3))  
☒ None of the above

B. Check all that apply:

- ☐ Tax-exempt entity (as described in 26 U.S.C. § 501)  
☐ Investment company, including hedge fund or pooled investment vehicle (as defined in 15 U.S.C. § 80a-3)  
☐ Investment advisor (as defined in 15 U.S.C. § 80b-2(a)(11))

C. NAICS (North American Industry Classification System) 4-digit code that best describes debtor. See <http://www.uscourts.gov/four-digit-national-association-naics-codes>.

3 2 5 4

**8. Under which chapter of the Bankruptcy Code is the debtor filing?**

Check one:

- ☐ Chapter 7  
☐ Chapter 9

☒ Chapter 11. Check **all** that apply:

A debtor who is a "small business debtor" must check the first sub-box. A debtor as defined in § 1182(1) who elects to proceed under subchapter V of chapter 11 (whether or not the debtor is a "small business debtor") must check the second sub-box.

- ☐ The debtor is a small business debtor as defined in 11 U.S.C. § 101(51D), and its aggregate noncontingent liquidated debts (excluding debts owed to insiders or affiliates) are less than \$3,024,725. If this sub-box is selected, attach the most recent balance sheet, statement of operations, cash-flow statement, and federal income tax return or if any of these documents do not exist, follow the procedure in 11 U.S.C. § 1116(1)(B).
- ☐ The debtor is a debtor as defined in 11 U.S.C. § 1182(1), its aggregate noncontingent liquidated debts (excluding debts owed to insiders or affiliates) are less than \$7,500,000, **and it chooses to proceed under Subchapter V of Chapter 11**. If this sub-box is selected, attach the most recent balance sheet, statement of operations, cash-flow statement, and federal income tax return, or if any of these documents do not exist, follow the procedure in 11 U.S.C. § 1116(1)(B).
- ☐ A plan is being filed with this petition.
- ☐ Acceptances of the plan were solicited prepetition from one or more classes of creditors, in accordance with 11 U.S.C. § 1126(b).
- ☒ The debtor is required to file periodic reports (for example, 10K and 10Q) with the Securities and Exchange Commission according to § 13 or 15(d) of the Securities Exchange Act of 1934. File the *Attachment to Voluntary Petition for Non-Individuals Filing for Bankruptcy under Chapter 11* (Official Form 201A) with this form.
- ☐ The debtor is a shell company as defined in the Securities Exchange Act of 1934 Rule 12b-2.

☐ Chapter 12**9. Were prior bankruptcy cases filed by or against the debtor within the last 8 years?**

- ☒ No  
☐ Yes

District

When

MM / DD / YYYY

Case number

If more than 2 cases, attach a separate list.

District

When

MM / DD / YYYY

Case number

Debtor Endo International plc Case number (if known) \_\_\_\_\_  
Name \_\_\_\_\_

10. **Are any bankruptcy cases pending or being filed by a business partner or an affiliate of the debtor?** ☐ No  
☒ Yes Debtor See Annex 1 Relationship Affiliate  
District Southern District of New York When Date hereof  
MM / DD / YYYY  
List all cases. If more than 1, attach a separate list.  
Case Number, if known \_\_\_\_\_

11. **Why is the case filed in *this* district?** *Check all that apply:*  
☐ Debtor has had its domicile, principal place of business, or principal assets in this district for 180 days immediately preceding the date of this petition or for a longer part of such 180 days than in any other district.  
☒ A bankruptcy case concerning debtor's affiliate, general partner, or partnership is pending in this district.

12. **Does the debtor own or have possession of any real property or personal property that needs immediate attention?** ☒ No  
☐ Yes. Answer below for each property that needs immediate attention. Attach additional sheets if needed.  
**Why does the property need immediate attention?** (*Check all that apply.*)  
☐ It poses or is alleged to pose a threat of imminent and identifiable hazard to public health or safety.  
What is the hazard?  
☐ It needs to be physically secured or protected from the weather.  
☐ It includes perishable goods or assets that could quickly deteriorate or lose value without attention (for example, livestock, seasonal goods, meat, dairy, produce, or securities-related assets or other options).  
☐ Other

**Where is the property?**

Number \_\_\_\_\_ Street \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_

**Is the property insured?**

☐ No  
☐ Yes Insurance agency \_\_\_\_\_  
Contact name \_\_\_\_\_  
Phone \_\_\_\_\_

**Statistical and administrative information**

13. **Debtor's estimation of available funds** *Check one:*  
☒ Funds will be available for distribution to unsecured creditors.  
☐ After any administrative expenses are paid, no funds will be available for distribution to unsecured creditors.  
14. **Estimated number of creditors**  
☐ 1-49 ☐ 1,000-5,000 ☐ 25,001-50,000  
☐ 50-99 ☐ 5,001-10,000 ☐ 50,001-100,000  
☐ 100-199 ☒ 10,001-25,000 ☐ More than 100,000  
☐ 200-999

Debtor Endo International plc Case number (if known) \_\_\_\_\_  
 Name

15. **Estimated assets**

<input type="checkbox"/> \$0-\$50,000	<input type="checkbox"/> \$1,000,001-\$10 million	<input type="checkbox"/> \$500,000,001-\$1 billion
<input type="checkbox"/> \$50,001-\$100,000	<input type="checkbox"/> \$10,000,001-\$50 million	<input checked="" type="checkbox"/> \$1,000,000,001-\$10 billion
<input type="checkbox"/> \$100,001-\$500,000	<input type="checkbox"/> \$50,000,001-\$100 million	<input type="checkbox"/> \$10,000,000,001-\$50 billion
<input type="checkbox"/> \$500,001-\$1 million	<input type="checkbox"/> \$100,000,001-\$500 million	<input type="checkbox"/> More than \$50 billion

16. **Estimated liabilities**

<input type="checkbox"/> \$0-\$50,000	<input type="checkbox"/> \$1,000,001-\$10 million	<input type="checkbox"/> \$500,000,001-\$1 billion
<input type="checkbox"/> \$50,001-\$100,000	<input type="checkbox"/> \$10,000,001-\$50 million	<input checked="" type="checkbox"/> \$1,000,000,001-\$10 billion
<input type="checkbox"/> \$100,001-\$500,000	<input type="checkbox"/> \$50,000,001-\$100 million	<input type="checkbox"/> \$10,000,000,001-\$50 billion
<input type="checkbox"/> \$500,001-\$1 million	<input type="checkbox"/> \$100,000,001-\$500 million	<input type="checkbox"/> More than \$50 billion

### Request for Relief, Declaration, and Signatures

**WARNING** -- Bankruptcy fraud is a serious crime. Making a false statement in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

17. **Declaration and signature of authorized representative of debtor**

The debtor requests relief in accordance with the chapter of title 11, United States Code, specified in this petition.  
 I have been authorized to file this petition on behalf of the debtor.  
 I have examined the information in this petition and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 08/16/2022  
 MM / DD / YYYY

/s/ Mark T. Bradley Mark T. Bradley  
 X Signature of authorized representative of debtor Printed name

Title Chief Financial Officer

### 18. Signature of attorney

/s/ Paul D. Leake Date 08/16/2022  
 X Signature of attorney for debtor MM / DD / YYYY

Paul D. Leake  
 Printed name

Skadden, Arps, Slate, Meagher & Flom LLP  
 Firm name

One Manhattan West  
 Number Street

New York New York 10001-8602  
 City State ZIP code

(212) 735-3000 paul.leake@skadden.com  
 Contact phone Email address

2313286 New York  
 Bar number State

## ANNEX 1 – AFFILIATED DEBTORS

The following list identifies all of the affiliated entities, including the Debtor filing this petition, that have filed voluntary petitions for relief in this Court under chapter 11 of title 11 of the United States Code, 11 U.S.C. §§ 101 *et seq.*, as amended, substantially contemporaneously with the filing of this petition.

	DEBTOR'S NAME	DEBTOR'S EIN
1.	Par Pharmaceutical, Inc.	22-2228342
2.	Actient Pharmaceuticals LLC	27-2717232
3.	70 Maple Avenue, LLC	90-0951491
4.	Endo International plc	68-0683755
5.	Anchen Incorporated	20-2008760
6.	Generics International (US), Inc.	26-1166489
7.	Anchen Pharmaceuticals, Inc.	68-0519179
8.	DAVA Pharmaceuticals, LLC	20-1207354
9.	Endo Par Innovation Company, LLC	81-1532435
10.	Generics Bidco I, LLC	26-1166905
11.	Innoteq, Inc.	26-3273381
12.	JHP Acquisition, LLC	36-4747861
13.	JHP Group Holdings, LLC	37-1707688
14.	Kali Laboratories, LLC	22-3494898
15.	Moore's Mill Properties L.L.C.	26-1309523
16.	Par Pharmaceutical Companies, Inc.	81-3078301
17.	Par Pharmaceutical Holdings, Inc.	77-0723135
18.	Par Sterile Products, LLC	26-0220105
19.	Par, LLC	20-0011286
20.	Quartz Specialty Pharmaceuticals, LLC	63-1255368
21.	Vintage Pharmaceuticals, LLC	63-1257882
22.	Actient Therapeutics LLC	45-4102019
23.	Astora Women's Health Ireland Limited	52-2035829
24.	Astora Women's Health, LLC	47-3330427
25.	Auxilium International Holdings, LLC	26-1629643
26.	Auxilium Pharmaceuticals, LLC	23-3016883
27.	Auxilium US Holdings, LLC	26-1628967
28.	Bermuda Acquisition Management Limited	N/A

	DEBTOR'S NAME	DEBTOR'S EIN
29.	BioSpecifics Technologies LLC	11-3054851
30.	Branded Operations Holdings, Inc.	85-3936945
31.	DAVA International, LLC	34-1969945
32.	Endo Aesthetics LLC	84-3630218
33.	Endo Bermuda Finance Limited	98-1254093
34.	Endo Designated Activity Company	98-1147135
35.	Endo Eurofin Unlimited Company	98-1522009
36.	Endo Finance IV Unlimited Company	98-1262779
37.	Endo Finance LLC	46-4766481
38.	Endo Finance Operations LLC	82-1446355
39.	Endo Finco Inc.	46-4765794
40.	Endo Generics Holdings, Inc.	46-0634834
41.	Endo Global Aesthetics Limited	98-1462898
42.	Endo Global Biologics Limited	98-1462735
43.	Endo Global Development Limited	98-1494785
44.	Endo Global Finance LLC	38-4007754
45.	Endo Global Ventures	98-1224244
46.	Endo Health Solutions Inc.	13-4022871
47.	Endo Innovation Valera, LLC	83-0973622
48.	Endo Ireland Finance II Limited	98-1300535
49.	Endo LLC	46-4266640
50.	Endo Luxembourg Finance Company I S.à r.l.	98-1143863
51.	Endo Luxembourg Holding Company S.à r.l.	98-1147168
52.	Endo Luxembourg International Financing S.à r.l.	98-1402905
53.	Endo Management Limited	98-1154866
54.	Endo Pharmaceuticals Finance LLC	82-1445768
55.	Endo Pharmaceuticals Inc.	52-2035829
56.	Endo Pharmaceuticals Solutions Inc.	04-3047911
57.	Endo Pharmaceuticals Valera Inc.	13-4119931
58.	Endo Procurement Operations Limited	98-1477840
59.	Endo TopFin Limited	98-1248086
60.	Endo U.S. Inc.	46-4710786
61.	Endo US Holdings Luxembourg I S.à r.l.	98-1247910
62.	Endo Ventures Aesthetics Limited	98-1529967

	DEBTOR'S NAME	DEBTOR'S EIN
63.	Endo Ventures Bermuda Limited	98-1160688
64.	Endo Ventures Cyprus Limited	98-1231544
65.	Endo Ventures Limited	98-1156029
66.	Generics International (US) 2, Inc.	30-0945075
67.	Generics International Ventures Enterprises LLC	83-1584685
68.	Hawk Acquisition Ireland Limited	98-1244776
69.	Kali Laboratories 2, Inc.	61-1796751
70.	Luxembourg Endo Specialty Pharmaceuticals Holding I S.à r.l.	98-1300601
71.	Paladin Labs Canadian Holding Inc.	N/A
72.	Paladin Labs Inc.	98-1181410
73.	Par Laboratories Europe, Ltd.	98-1319597
74.	Par Pharmaceutical 2, Inc.	30-0944895
75.	Slate Pharmaceuticals, LLC	26-0456201
76.	Timm Medical Holdings, LLC	27-0468744



## Secretary's Certificate

Attached hereto as **Annex A** is a true, correct, and complete copy of the resolutions duly adopted by the Board of Directors of the Company on August 12, 2022 (the “**Resolutions**”), and such Resolutions have not been modified or rescinded in whole, in part, or in any respect and are in full force and effect

Endo International plc

DocuSigned by:  
Matthew Maletta  
85E3903517794E3...

Title: Executive Vice President, Chief Legal Officer and Company Secretary

**Annex A**

---

**ENDO INTERNATIONAL plc  
MEETING OF THE  
BOARD OF DIRECTORS**

**August 12, 2022**

---

**WHEREAS**, the Board of Directors (the “Board”) of Endo International plc, an Irish public limited company (the “Company”), has considered presentations by the management of, and the financial and legal advisors to, the Company regarding the liabilities and liquidity situation of the Company, the strategic alternatives available to it, and the effect of the foregoing on the Company’s business, creditors, and other parties-in-interest;

**WHEREAS**, the Board has had the opportunity to consult with the Company’s management, and financial and legal advisors and other professionals, and fully consider each of the strategic alternatives available to the Company;

**WHEREAS**, based on its review of all available alternatives and advice provided by such advisors and professionals, the Board has determined that it is in the best interest of the Company, its subsidiaries, and its and their respective creditors, stakeholders, and other parties-in-interest, for the Company and its subsidiaries to take the actions specified in the following resolutions;

*Chapter 11 Case*

**WHEREAS**, the Board has been presented with a proposed petition to be filed by the Company in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) seeking relief under the provisions of chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”), in which the authority to operate as a debtor-in-possession will be sought;

**WHEREAS**, the Board, having considered the financial and operational aspects of the Company’s business and the best course of action to maximize value, deems it advisable and in the best interests of the Company, its subsidiaries, and its and their respective creditors, stakeholders, and other parties-in-interest, that a petition be filed by the Company seeking relief under the provisions of chapter 11 of the Bankruptcy Code; and

*Restructuring Support Agreement*

**WHEREAS**, the Board has been presented with a proposed Restructuring Support Agreement (the “RSA”) by and among each of (a) the Company, for itself and each of its direct and indirect subsidiaries listed on Exhibit A to the RSA, and (b) the Consenting First Lien Creditors, each as defined therein, on or in advance of the date hereof; for the avoidance of doubt, the RSA includes the Restructuring Term Sheet (as defined therein) and each other exhibit thereto, all substantially in the forms and on the terms presented to the Board.

### *Outstanding Contingencies*

**WHEREAS**, the Board has been advised by the Company’s management and advisors that, at the time of adoption of these Resolutions, the following items remain unresolved: (1) whether holders of more than 50% of the aggregate face amount of the Company’s first lien indebtedness will agree to execute the RSA (the “1L Support Contingency”) and (2) provisions in the Restructuring Term Sheet pertaining to the treatment of certain liabilities described to the Board (the “Liabilities Contingency”).

**WHEREAS**, the following resolutions shall be conditioned in all respects upon the satisfactory resolution of the 1L Support Contingency and the Liabilities Contingency, as determined in the reasonable discretion of any Authorized Officer (as defined below), by no later than Tuesday, August 16, 2022 (the “Resolutions End Date”); provided, that, in the event that the 1L Support Contingency and/or the Liabilities Contingency are not resolved by the Resolutions End Date, the Chair of the Board and the Chief Executive of the Company may jointly determine to extend the Resolutions End Date or may request a meeting of the Board to further consider any remaining contingency.

### **NOW THEREFORE, BE IT:**

#### Chapter 11 Case

**RESOLVED**, that in the judgment of the Board it is desirable and in the best interests of the Company, its subsidiaries, and its and their respective creditors, stakeholders, and other parties-in-interest, that a voluntary petition be filed by the Company seeking relief under the provisions of chapter 11 of the Bankruptcy Code, and the filing of such petition is authorized hereby; and be it further

**RESOLVED**, that the Chief Executive Officer of the Company, Chief Financial Officer of the Company, or any Executive or Senior Vice President of the Company (or their designees) (the “Authorized Officers” and each individually an “Authorized Officer”), is hereby authorized and empowered, on behalf of and in the name of the Company, to execute and verify a petition in the name of the Company under chapter 11 of the Bankruptcy Code and to cause the same to be filed in the Bankruptcy Court in such form and at such time as the Authorized Officer(s) executing said petition on behalf of the Company shall determine; and be it further

#### Restructuring Support Agreement

**RESOLVED**, that in connection with the chapter 11 case, the Board has determined it is desirable and in the best interests of the Company, its subsidiaries, and its and their respective creditors, stakeholders, and other parties-in-interest, that the Company shall be, and hereby is, authorized to enter into the RSA, in substantially the form presented to the Board and with such other changes, additions, and modifications thereto as an Authorized Officer executing the same shall approve, such approval to be conclusively evidenced by an Authorized Officer’s execution and delivery thereof; and be it further

**RESOLVED**, that the Authorized Officers are empowered, authorized and directed, with full power of delegation, on behalf of the Company, to cause the Company to negotiate, execute, and deliver the RSA and any related documents contemplated thereby, in such form and with such changes or amendments as any one or more such Authorized Officers shall approve as necessary or desirable; and be it further

### Regulatory Filings

**RESOLVED**, that in order for the Company and its applicable subsidiaries to comply with all requirements under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”) and any applicable state securities laws or requirements of the Nasdaq Global Select Market, the Authorized Officers are authorized and empowered, on behalf of the Company and its applicable subsidiaries, with the assistance of counsel, to take all action necessary, appropriate or advisable to cause to be prepared, executed and filed, all reports, statements, documents and information related to the chapter 11 case required to be filed by the Company and its applicable subsidiaries, and to take all other action necessary, appropriate or advisable in connection with the Exchange Act and any applicable federal or state securities laws or requirements of the Nasdaq Global Select Market, including one or more Current Reports on Form 8-K and notifications to the Nasdaq Global Select Market; and be it further

### Retention of Advisors

**RESOLVED**, that the Authorized Officers of the Company be, and each of them hereby is, authorized and empowered, on behalf of and in the name of the Company, to retain and employ professionals to render services to the Company in connection with the chapter 11 case and the transactions contemplated by the foregoing resolutions, including, without limitation, the law firm Skadden, Arps, Slate, Meagher & Flom LLP, to act as chapter 11 counsel; Togut, Segal & Segal LLP, to act as co-counsel; Alvarez & Marsal Holdings, LLC, to act as financial advisor; PJT Partners L.P., to act as investment banker; and Kroll, LLC to act as claims and noticing agent and administrative advisor; and in connection therewith each Authorized Officer is hereby authorized and directed to execute appropriate retention agreements, pay appropriate retainers, and to cause to be filed appropriate applications for authority to retain the services of the foregoing; and be it further

### General Resolutions

**RESOLVED**, that the Authorized Officers of the Company be, and each of them hereby is, authorized and empowered, on behalf of and in the name of the Company, to execute, deliver, perform, verify or file, or cause to be executed, delivered, performed, verified or filed (or direct others to do so on their behalf as provided herein) all necessary documents, including, without limitation, all petitions, affidavits, statements, schedules, motions, lists, applications, pleadings, other papers, security documents, guarantees, reaffirmations, control agreements, waivers of or amendments to existing documents, and to negotiate the forms, terms and provisions of, and to execute and deliver any amendments, modifications, waivers or consents to any of the foregoing as may be approved by any Authorized Officer, which amendments, modifications, waivers or consents may provide for consent payments, fees or other amounts payable or other modifications of or relief under such agreements or documents, the purpose of such amendments, modifications, waivers or consents being to facilitate consummation of the transactions contemplated by the foregoing resolutions or for any other purpose, and, in connection with the foregoing, to employ and retain all assistance by legal counsel, investment bankers, accountants, restructuring professionals or other professionals, and to take any and all action which such Authorized Officer deems necessary or proper in connection with the chapter 11 case, with a view to the successful prosecution of the chapter 11 case contemplated by the foregoing resolutions and the successful consummation of the transactions contemplated by the foregoing resolutions, including, without limitation, any action necessary or proper to maintain the ordinary course operation of the Company’s business; and be it further

**RESOLVED**, that the Authorized Officers of the Company be, and each of them hereby is, authorized to execute, deliver and perform any and all special powers of attorney as such Authorized Officer may deem necessary or desirable to facilitate consummation of the transactions contemplated by the foregoing resolutions, pursuant to which such Authorized Officer will make certain appointments of attorneys to facilitate consummation of the transactions contemplated by the foregoing resolutions as the Company's true and lawful attorneys and authorize each such attorney to execute and deliver any and all documents of whatsoever nature and description that may be necessary or desirable to facilitate consummation of the transactions contemplated by the foregoing resolutions; and be it further

**RESOLVED**, that all acts lawfully done or actions lawfully taken by any Authorized Officer to seek relief on behalf of the Company under chapter 11 of the Bankruptcy Code, or in connection with the chapter 11 case, or any matter related thereto, be, and hereby are, adopted, ratified, confirmed, and approved in all respects as the acts and deeds of the Company in all respects by the Board of the Company; and be it further

**RESOLVED**, that all acts lawfully done or actions lawfully taken by any Authorized Officer, or by any employees or agents of the Company, on or before the date hereof in connections with the transactions contemplated by the foregoing resolutions be, and they hereby are, ratified, confirmed and approved in all respects by the Board of the Company; and be it further

**RESOLVED**, that the omission from these resolutions of any agreement, document or other arrangement contemplated by any of the agreements, instruments, filings or other documents described in the foregoing resolutions or any action to be taken in accordance with any requirement of any of the agreements, instruments, filings or other documents described in the foregoing resolutions shall in no manner derogate from the authority of the Authorized Officers to take all actions necessary, desirable, proper, advisable or appropriate to consummate, effectuate, carry out or further the transaction contemplated by, and the intent and purposes of, the foregoing resolutions; and be it further

**RESOLVED**, that the authority conferred upon any Authorized Officer of the Company by these resolutions is in addition to, and shall in no way limit, such other authority as such Authorized Officer may have with respect to the subject matter of the foregoing resolutions, and that the omission from these resolutions of any agreement or other arrangement contemplated by any of the agreements, instruments or documents described in the foregoing resolutions or any action to be taken in accordance with any requirement of any of the agreements, instruments or documents described in the foregoing resolutions shall in no manner derogate from the authority of any Authorized Officer to take any and all actions convenient, necessary, advisable or appropriate to consummate, effectuate, carry out, perform or further the transactions contemplated by, and the intents and purposes of, the foregoing resolutions; and be it further

**RESOLVED**, the Board has received sufficient notice of the actions and transactions relating to the matters contemplated by the foregoing resolutions, as may be required by the organizational documents of the Company, or hereby waive any right to have received such notice; and be it further

**RESOLVED**, that each of the Authorized Officers (and their designees and delegates) be, and hereby are, authorized and empowered to take all actions or not to take any action in the name of the Company with respect to the transactions contemplated by these

resolutions hereunder as the sole shareholder, partner, member, managing member, manager (or similar role) of each subsidiary of the Company, in each case, as such Authorized Officers or Authorized Officers shall deem necessary proper, appropriate, desirable or advisable to effectuate the purposes of the transactions contemplated herein; and be it further

**RESOLVED**, that these resolutions be filed with the records of meetings of the Board.

\* \* \*

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

Paul D. Leake

Lisa Laukitis

Shana A. Elberg

Evan A. Hill

One Manhattan West

New York, New York 10001

Telephone: (212) 735-3000

Fax: (212) 735-2000

*Proposed Counsel to Debtors and Debtors in Possession*

*In re*

**ENDO INTERNATIONAL plc, et al.,**

**Debtors.<sup>1</sup>**

**Chapter 11**

**Case No. [ ]-[ ] ([ ])**

**(Joint Administration Pending)**

**EXHIBIT A**

**ATTACHMENT TO VOLUNTARY PETITION FOR  
NON-INDIVIDUALS FILING FOR BANKRUPTCY UNDER CHAPTER 11**

1. If any of the debtor's securities are registered under Section 12 of the Securities Exchange Act of 1934, the SEC file number is: 001-36326

2. The following financial data is the latest available information and refers to the debtor's condition on June 30, 2022 (unless otherwise indicated).

(a) Total Assets: \$6,330,717,000

(b) Total Debts: \$9,535,279,000

(c) Debt securities held by more than 500 holders:

<b>Debt Security</b>	<b>Secured/Unsecured/ Subordinated</b>	<b>Principal Amount (\$)</b>	<b>Approximate Number of Holders</b>
7.50% Senior Secured Notes due 2027	Secured	\$2,015,479,000	Unknown CUSIP: 69888XAA7

<sup>1</sup> The last four digits of Debtor Endo International plc's tax identification number are 3755. Due to the large number of debtors in these chapter 11 cases, a complete list of the debtor entities and the last four digits of their federal tax identification numbers is not provided herein. A complete list of such information may be obtained on the website of the Debtors' claims and noticing agent at <https://restructuring.ra.kroll.com/Endo>. The location of the Debtors' service address for purposes of these chapter 11 cases is: 1400 Atwater Drive, Malvern, PA 19355.

Debt Security	Secured/Unsecured/ Subordinated	Principal Amount (\$)	Approximate Number of Holders
6.125% Senior Secured Notes due 2029	Secured	\$1,295,000,000	Unknown CUSIP: 29280BAA3
9.50% Senior Secured Second Lien Notes due 2027	Secured	\$940,590,000	Unknown CUSIP: 29273DAB6
5.875% Senior Secured Notes due 2024	Secured	\$300,000,000	Unknown CUSIP: 29273DAA8
6.00% Senior Notes due 2028	Unsecured	\$1,260,416,000	Unknown CUSIP: 29273DAC4
6.00% Senior Notes due 2023	Unsecured	\$56,436,000	Unknown CUSIP: 29273EAC2
6.00% Senior Notes due 2025	Unsecured	\$21,578,000	Unknown CUSIP: 29273EAA6
5.375% Senior Notes due 2023	Unsecured	\$6,127,000	Unknown CUSIP: 29271LAE4

(d) Number of shares of preferred stock: 0

(e) Number of shares of common stock: 235,142,889<sup>2</sup>

Comments, if any: N/A

3. Brief description of debtor's business:

Endo International plc is a generics and branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization.

4. List the names of any person who directly or indirectly owns, controls, or holds, with power to vote, 5% or more of the voting securities of debtor:

Owner	Percentage of Ownership <sup>3</sup>
The Vanguard Group, Inc.	12.07%
BlackRock, Inc.	7.93%
Paulson & Co., Inc.	7.37%
Renaissance Technologies LLC	7.07%

<sup>2</sup> As of August 1, 2022.

<sup>3</sup> Percentage holdings as of August 2, 2022.



SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP  
Paul D. Leake  
Lisa Laukitis  
Shana A. Elberg  
Evan A. Hill  
One Manhattan West  
New York, New York 10001  
Telephone: (212) 735-3000  
Fax: (212) 735-2000

*Proposed Counsel to Debtors and Debtors in Possession*

***In re***

**ENDO INTERNATIONAL plc, et al.,**

**Debtors.<sup>1</sup>**

**Chapter 11**

**Case No. [ ]-[ ] ([ ])**

**(Joint Administration Pending)**

**CONSOLIDATED CORPORATE OWNERSHIP  
STATEMENT AND LIST OF EQUITY SECURITY HOLDERS  
PURSUANT TO FEDERAL RULES OF BANKRUPTCY PROCEDURE 1007 AND 7007.1**

Pursuant to Rules 1007(a)(1) and 7007.1 of the Federal Rules of Bankruptcy Procedure and Rule 1007-3 of the Local Bankruptcy Rules for the Southern District of New York, Endo International plc and its debtor affiliates, as debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the “Debtors”), respectfully represent:

1. Endo International plc is a publicly traded corporation. The Vanguard Group, Inc. owns 12.07%.<sup>2</sup> No other entities have a direct or indirect ownership interest of 10% or more in Endo International plc.

<sup>1</sup> The last four digits of Debtor Endo International plc's tax identification number are 3755. Due to the large number of debtors in these chapter 11 cases, a complete list of the debtor entities and the last four digits of their federal tax identification numbers is not provided herein. A complete list of such information may be obtained on the website of the Debtors' claims and noticing agent at <https://restructuring.ra.kroll.com/Endo>. The location of the Debtors' service address for purposes of these chapter 11 cases is: 1400 Atwater Drive, Malvern, PA 19355.

<sup>2</sup> As of August 8, 2022.

2. Endo International plc owns 100% of the equity interests in Endo Designated Activity Company.

3. Endo Designated Activity Company owns 100% of the equity interests in Endo Finance IV Unlimited Company.

4. Endo Finance IV Unlimited Company owns 100% of the equity interests in Endo Management Limited.

5. Endo Management Limited owns 100% of the equity interests in the following Debtors: Endo Procurement Operations Limited; Endo TopFin Limited; Endo Global Development Limited; and Endo Ventures Aesthetics Limited.

6. Endo TopFin Limited owns 100% of the equity interests in the following Debtors: Endo Ventures Limited and Endo Ventures Cyprus Limited.

7. Endo Ventures Limited owns 100% of the equity interests in the following Debtors: Endo Global Aesthetics Limited; Endo Global Biologics Limited; Generics International Ventures Enterprises LLC.

8. Endo Ventures Limited owns 98.99% of the equity interests in Endo Luxembourg Holding Company S.à r.l. and Endo Bermuda Ventures Limited owns 1.01% of the equity interests in Endo Luxembourg Holding Company S.à r.l.

9. Endo Ventures Cyprus Limited owns 55% of the common shares of Endo Global Ventures. Endo Designated Activity Company owns 45% of the common shares and 100% of the non-qualified preferred shares Endo Global Ventures.

10. Endo Ventures Cyprus Limited owns 100% of the equity interests in Endo Ventures Bermuda Limited.

11. Endo Luxembourg Holding Company S.à r.l. owns 100% of the equity interests in Endo Luxembourg Finance Company I S.à r.l.

12. Endo Luxembourg Finance Company I S.à r.l. owns 100% of the equity interests in the following Debtors: Par Pharmaceutical Holdings, Inc.; Endo Global Finance LLC; Paladin Labs Canadian Holding Inc.; Endo LLC; Endo Ireland Finance II Limited; and Endo Finco Inc.

13. Par Pharmaceutical Holdings, Inc. owns 100% of the equity interests in the following Debtors: Par Pharmaceutical Companies, Inc. and Luxembourg Endo Specialty Pharmaceuticals Holding I S.à r.l.

14. Endo Global Finance LLC owns 100% of the equity interests in Endo Finance Operations LLC.

15. Paladin Labs Canadian Holding Inc. owns 100% of the equity interests in Paladin Labs Inc.

16. Endo Ireland Finance II Limited owns 100% of the equity interests in the following Debtors: Endo Eurofin Unlimited Company and Endo Bermuda Finance Limited.

17. Endo Eurofin Unlimited Company owns 100% of the equity interests in Endo U.S. Inc.

18. Endo U.S. Inc. owns 100% of the equity interests in the following Debtors: Endo U.S. Holdings Luxembourg I S.à r.l. and Endo Health Solutions Inc.

19. Par Pharmaceutical Companies, Inc. owns 100% of the equity interests in Par Pharmaceutical, Inc.

20. Par Pharmaceutical, Inc. owns 100% of the equity interests in the following Debtors: BioSpecifics Technologies LLC; Par Laboratories Europe, Ltd.; Innoteq, Inc.; Endo

Finance LLC; Generics International (US), Inc.; Kali Laboratories, LLC; Endo Par Innovation Company, LLC; Par, LLC; non-Debtor Par Formulations Private Limited; Anchen Incorporated and JHP Group Holdings, LLC.

21. Generics International (US), Inc. owns 100% of the equity interests in the following Debtors: Moores Mill Properties L.L.C.; Vintage Pharmaceuticals, LLC, DAVA Pharmaceuticals, LLC ,and Generics Bidco I, LLC.

22. Anchen Incorporated owns 100% of the equity interests in Anchen Pharmaceuticals, Inc.

23. JHP Group Holdings, LLC owns 100% of the equity interests in JHP Acquisition, LLC.

24. Generics Bidco I, LLC owns 50% of the equity interests in Quartz Specialty Pharmaceuticals, LLC. Vintage Pharmaceuticals LLC also owns 50% of the equity interests.

25. DAVA Pharmaceuticals, LLC owns 100% of the equity interests in DAVA International, LLC.

26. JHP Acquisition, LLC owns 100% of the equity interests in Par Sterile Products, LLC.

27. Endo Health Solutions Inc. owns 100% of the equity interests in the following Debtors: Endo Aesthetics LLC; Hawk Acquisition Ireland Limited; Endo Luxembourg International Financing S.à r.l; and Bermuda Acquisition Management Limited.

28. Hawk Acquisition Ireland Limited owns 100% of the equity interests in Endo Generics Holdings, Inc.

29. Endo Generics Holdings, Inc. owns 100% of the equity interests in the following Debtors: Par Pharmaceutical 2, Inc. and Kali Laboratories 2, Inc.

30. Par Pharmaceutical 2, Inc. owns 100% of the equity interests in Endo Pharmaceuticals Inc. and Branded Operations Holdings, Inc.

31. Branded Operations Holdings, Inc. owns 100% of the equity interests in the following Debtors: Endo Pharmaceuticals Solutions Inc., Generics International (US) 2, Inc., and Endo Pharmaceuticals Finance LLC.

32. Endo Pharmaceuticals Inc. owns 100% of the equity interests in the following Debtors: Astora Women's Health, LLC and Astora Women's Health Ireland Limited.

33. Astora Women's Health, LLC owns 100% of the equity interests in non-Debtor Astora Women's Health Technologies.

34. Generics International (US) 2, Inc. owns 100% of the equity interests in Auxilium Pharmaceuticals, LLC.

35. Auxilium Pharmaceuticals, LLC owns 100% of the equity interests in the following Debtors: Auxilium US Holdings, LLC, Auxilium International Holdings, LLC, and Actient Pharmaceuticals LLC.

36. Actient Pharmaceuticals LLC owns 100% of the equity interests in the following Debtors: Slate Pharmaceuticals, LLC; 70 Maple Avenue, LLC; Timm Medical Holdings, LLC; and Actient Therapeutics, LLC.

37. Actient Pharmaceuticals LLC owns 95% of the common shares of Actient Therapeutics, LLC. Slate Pharmaceuticals, LLC owns 5% of the common shares and 100% of the preferred shares.

38. Endo Pharmaceuticals Solutions Inc. owns 100% of the equity interests in Endo Pharmaceuticals Valera Inc and 65% of the membership interests in non-Debtor CPEC LLC. An unaffiliated third party owns a 35% membership interest in CPEC LLC.

39. Endo Pharmaceuticals Valera Inc. owns 100% of the equity interests in Endo Innovation Valera, LLC.

### Top Unsecured Creditors

Name of creditor and complete mailing address, including zip code		Name, telephone number, and email address of creditor contact	Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts)	Indicate if claim is contingent, unliquidated, or disputed	Amount of unsecured claim		
					If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
					Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
1	WELLS FARGO BANK , NATIONAL ASSOCIATION - 6.00% SENIOR NOTES DUE 2028 AS INDENTURE TRUSTEE CORPORATE TRUST SERVICES—ADMINISTRATOR FOR ENDO 6.000 SENIOR NOTES DUE 2028 150 EAST 42ND STREET, 40TH FLOOR NEW YORK, NY 10017	ATTN: TINA GONZALEZ TITLE: VICE PRESIDENT PHONE: 617-574-6363 EMAIL: TINA.GONZALEZ@WELLSFARGO.COM	6.00% SENIOR NOTES DUE 2028				\$ 1,269,399,075
2	AMERISOURCEBERGEN CORPORATION 9075 CENTRE POINT DRIVE SUITE 140 WEST CHESTER, OH 45069	ATTN: MELISSA RAND TITLE: SENIOR COUNSEL PHONE: 610-727-2734 EMAIL: MELISSA.RAND@AMERISOURCEBERGEN.COM	DISTRIBUTOR FEES	UNLIQUIDATED			\$ 200,612,057
3	MCKESSON CORPORATION 9954 MARYLAND DR STE 4000 HENRICO, VA 23233	ATTN: BEN CARLSEN TITLE: MANAGING LEAD COUNSEL PHONE: 404-461-4232 EMAIL: BEN.CARLSEN@MCKESSON.COM	DISTRIBUTOR FEES	UNLIQUIDATED			\$ 193,515,782
4	CARDINAL HEALTH 7000 CARDINAL PLACE DUBLIN, OH 43017	ATTN: DEBRA A. WILLET TITLE: VICE PRESIDENT & ASSOCIATE GENERAL COUNSEL PHONE: 614-757-3428 EMAIL: DEBRA.WILLET@CARDINALHEALTH.COM	DISTRIBUTOR FEES	UNLIQUIDATED			\$ 151,356,517
5	WELLS FARGO BANK , NATIONAL ASSOCIATION - 6.00% SENIOR NOTES DUE 2023 AS INDENTURE TRUSTEE CORPORATE TRUST SERVICES—ADMINISTRATOR FOR ENDO HEALTH SOLUTIONS INC. 150 EAST 42ND STREET, 40TH FLOOR NEW YORK, NY 10017	ATTN: TINA GONZALEZ TITLE: VICE PRESIDENT PHONE: 617-574-6363 EMAIL: TINA.GONZALEZ@WELLSFARGO.COM	6.00% SENIOR NOTES DUE 2023				\$ 58,419,055
6	COMMISSIONER OF SOCIAL SERVICES DRUG REHAB PROGRAM PO BOX 2951 HARTFORD, CT 06104	ATTN: DR. KILOLO KIJAKAZI TITLE: ACTING COMMISSIONER PHONE: 203-576-7416 EMAIL:	CUSTOMER BALANCES	UNLIQUIDATED			\$ 22,977,562
7	WELLS FARGO BANK , NATIONAL ASSOCIATION - 6.00% SENIOR NOTES DUE 2025 AS INDENTURE TRUSTEE CORPORATE TRUST SERVICES—ADMINISTRATOR FOR ENDO HEALTH SOLUTIONS INC. 150 EAST 42ND STREET, 40TH FLOOR NEW YORK, NY 10017	ATTN: TINA GONZALEZ TITLE: VICE PRESIDENT PHONE: 617-574-6363 EMAIL: TINA.GONZALEZ@WELLSFARGO.COM	6.00% SENIOR NOTES DUE 2025				\$ 22,275,410
8	CONNECTIVERX 200 JEFFERSON PARK WHIPPANY, NJ 07981	ATTN: JIM CORRIGAN TITLE: CHIEF EXECUTIVE OFFICER PHONE: 201-358-7200 EMAIL: JCORRIGAN@CONNECTIVERX.COM	CUSTOMER BALANCES	UNLIQUIDATED			\$ 15,795,879
9	MORRIS AND DICKSON COMPANY LTD 410 KAY LANE SHREVEPORT, LA 71115	ATTN: JODY HATCHER TITLE: CHIEF EXECUTIVE OFFICER PHONE: 318-797-7900 EMAIL: JHATCHER@MORRISDICKSON.COM	DISTRIBUTOR FEES	UNLIQUIDATED			\$ 12,854,435
10	COLORADO HEALTH CARE POLICY 1570 GRANT STREET DENVER, CO 80203	ATTN: KIM BIMESTEFER TITLE: EXECUTIVE DIRECTOR PHONE: 303-866-4411 EMAIL: KIM.BIMESTEFER@STATE.CO.US	PAYOR REBATES	UNLIQUIDATED			\$ 12,604,165
11	CVS/ PHARMACY, INC., ONE CVS DRIVE WOONSOCKET, RI 02895	ATTN: BRIAN E. WHALEN TITLE: SVP, PHARMACY TRADE & SUPPLY CHAIN PHONE: 401-770-4661 EMAIL: BRIAN.WHALEN@CVSHEALTH.COM	DISTRIBUTOR FEES	UNLIQUIDATED			\$ 12,540,335
12	NYS DEPARTMENT OF HEALTH EMPIRE STATE PLAZA ALBANY, NY 12237	ATTN: MARY T. BASSETT TITLE: COMMISSIONER PHONE: 518-402-7950 EMAIL: CMR@HEALTH.NY.GOV	PAYOR REBATES	UNLIQUIDATED			\$ 9,006,690
13	OPTUM, INC. 11000 OPTUM CIRCLE EDEN PRAIRIE, MN 55344	ATTN: HEATHER CIANFROCCO TITLE: CHIEF EXECUTIVE OFFICER PHONE: 412-480-4104 EMAIL: HEATHER.CIANFROCCO@UHC.COM	CUSTOMER BALANCES	UNLIQUIDATED			\$ 8,880,617
14	WELLS FARGO BANK , NATIONAL ASSOCIATION - 5.375% SENIOR NOTES DUE 2023 AS INDENTURE TRUSTEE CORPORATE TRUST SERVICES—ADMINISTRATOR FOR ENDO HEALTH SOLUTIONS INC. 150 EAST 42ND STREET, 40TH FLOOR NEW YORK, NY 10017	ATTN: TINA GONZALEZ TITLE: VICE PRESIDENT PHONE: 617-574-6363 EMAIL: TINA.GONZALEZ@WELLSFARGO.COM	5.375% SENIOR NOTES DUE 2023				\$ 6,319,865
15	TPA 17 TECHNOLOGY CIRCLE COLUMBIA, SC 29203	ATTN: JOE JOHNSON TITLE: PRESIDENT AND CHIEF OPERATING OFFICER PHONE: 803-735-1034 EMAIL:	CUSTOMER BALANCES	UNLIQUIDATED			\$ 6,133,385
16	CALIFORNIA DEPARTMENT OF HEALTH CARE 1500 CAPITOL AVE MS 7602 SACRAMENTO, CA 95814	ATTN: TOMAS J. ARAGON TITLE: DIRECTOR PHONE: 800-495-3232 EMAIL: TOMAS.ARAGON@SFDPH.ORG	PAYOR REBATES	UNLIQUIDATED			\$ 6,082,026
17	MALLINCKRODT PHARMACEUTICALS 675 MCDONNELL BLVD HAZELWOOD, MO 63042	ATTN: MARK CASEY TITLE: EXECUTIVE VICE PRESIDENT AND CHIEF LEGAL OFFICER PHONE: 617-225-0078 EMAIL: MARK.CASEY@CYTYC.COM	PROFIT SHARING	UNLIQUIDATED			\$ 5,787,813
18	MERCK SHARP AND DOHME INTERNATIONAL POSTBUS 581 HAARLEM, 2003 PC NETHERLAND	ATTN: CAROLINE LITCHFIELD TITLE: EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER PHONE: 908-359-0188 EMAIL: CAROLINE_LITCHFIELD@MERCK.COM	PROFIT SHARING / TRADE DEBT	UNLIQUIDATED			\$ 4,166,712
19	PA DEPARTMENT OF HUMAN SERVICES 625 FORESTER STREET HARRISBURG, PA 17120	ATTN: MEG SNEAD TITLE: SECRETARY OF HUMAN SERVICES PHONE: 920-739-0884 EMAIL: COSTELLOMEG@GMAIL.COM	PAYOR REBATES	UNLIQUIDATED			\$ 3,951,986



Top Unsecured Creditors

Name of creditor and complete mailing address, including zip code		Name, telephone number, and email address of creditor contact	Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts)	Indicate if claim is contingent, unliquidated, or disputed	Amount of unsecured claim		
					If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
					Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
20	WALGREENS 200 WILMOT ROAD DEERFIELD, IL 60015	ATTN: LISA BADGLEY TITLE: SENIOR VICE PRESIDENT PHONE: 847-945-0611 EMAIL: LISA.BADGLEY@WALGREENS.COM	DISTRIBUTOR FEES	UNLIQUIDATED			\$ 3,093,085
21	UROGPO LLC 600 SUPERIOR AVENUE EAST STE 1500 CLEVELAND, OH 44114	ATTN: DAVID COURY TITLE: CHIEF EXECUTIVE OFFICER PHONE: 216-292-9998 EMAIL: DAVID.COURY@UROGPO.US.COM	CUSTOMER BALANCES	UNLIQUIDATED			\$ 3,044,956
22	NORTH CAROLINA DHHS DRUG REBATE - C 2001 MAIL SERVICE CENTER RALEIGH, NC 27699-2000	ATTN: KODY KINSLEY TITLE: SECRETARY OF HEALTH AND HUMAN SERVICES PHONE: 919-855-4800 EMAIL:	PAYOR REBATES	UNLIQUIDATED			\$ 2,784,703
23	ALLERGAN USA INC 5 GIRALDA FARMS MADISON, NJ 07940	ATTN: RICHARD A GONZALEZ TITLE: CHIEF EXECUTIVE OFFICER PHONE: 862-261-7000 EMAIL: RICHARD.GONZALEZ@ABBVIE.COM	PROFIT SHARING	UNLIQUIDATED			\$ 2,716,312
24	AGENCY FOR HEALTH CARE ADMINISTRATION 2727 MAHAN DRIVE TALLAHASSEE, FL 32308	ATTN: CODY L. FARRILL TITLE: CHIEF OF STAFF PHONE: 850-412-3600 EMAIL: CODY.FARRILL@DOT.STATE.FL.US	CUSTOMER BALANCES	UNLIQUIDATED			\$ 2,708,094
25	STATE OF KENTUCKY - DMS 275 E. MAIN ST. 6W-A FRANKFORT, KY 40621	ATTN: ERIC FRIEDLANDER TITLE: SECRETARY PHONE: 502-561-9179 EMAIL: FRIEDLANDER@LOUISVILLEKY.GOV	PAYOR REBATES	UNLIQUIDATED			\$ 2,109,882
26	VIRGINIA DEPT. OF MED ASSISTANCE SERVICES 600 EAST BROAD STREET RICHMOND, VA 23219	ATTN: MICHAEL H. COOK ESQ. TITLE: CHAIR, BOARD OF MEDICAL ASSISTANCE SERVICES PHONE: 804-786-7933 EMAIL:	PAYOR REBATES	UNLIQUIDATED			\$ 2,095,558
27	DEERFIELD GENERICS LP 345 PARK AVENUE SOUTH 12TH FL NEW YORK, NY 10010	ATTN: KAREN HEIDELBERGER TITLE: INVESTMENT AND PARTNERSHIP PHONE: 212-984-7112 EMAIL: KARENH1@DEERFIELD.COM	PROFIT SHARING	UNLIQUIDATED			\$ 2,021,455
28	SMITH DRUG COMPANY 9098 FAIRFOREST RD SPARTANBURG, SC 29301	ATTN: WADE LEWIS TITLE: PRESIDENT PHONE: 864-574-8161 EMAIL: WLEWIS@SMITHDRUG.COM	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,985,505
29	BAYER AG KAISER WILHELM ALLEE LEVERKUSEN, 51373 GERMANY	ATTN: WERNER BAUMANN TITLE: CHIEF EXECUTIVE OFFICER PHONE: 972-377-1950 EMAIL: WERNER.BAUMANN@BAYERHEALTHCARE.COM	TRADE DEBT				\$ 1,961,911
30	TREASURER STATE OF OHIO 30 E. BROAD STREET - 9TH FLOOR COLUMBUS, OH 43215	ATTN: ROBERT SPRAGUE TITLE: TREASURER PHONE: 800-228-1102 EMAIL: RSPRAGUE@CI.FINDLAY.OH.US	PAYOR REBATES	UNLIQUIDATED			\$ 1,944,839
31	ASCENT 77 DRESSER STREET SOUTH BOSTON, MA 02127	ATTN: MARK SAGON TITLE: MANAGING PARTNER PHONE: 646-964-3850 EMAIL: MPSAGON@GMAIL.COM	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,831,832
32	ANDA INC. 2915 WESTON ROAD WESTON, FL 33331	ATTN: SVEN DETHLEFS TITLE: EXECUTIVE VICE PRESIDENT PHONE: 972-391-4817 EMAIL: SVEN.DETHLEFS@TEVAPHARM.COM	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,818,276
33	JOHNSON CONTROLS INC 4700 EXCHANGE COURT STE 300 BOCA RATON, FL 33431	ATTN: GEORGE R. OLIVER TITLE: CHAIRMAN AND CEO PHONE: 888-981-4544 EMAIL: GEORGE.OLIVER@JCI.COM	TRADE DEBT				\$ 1,489,674
34	ARIZONA HEALTH CARE COST CONTAINMENT SYSTEMS 801 E JEFFERSON ST PHOENIX, AZ 85034	ATTN: JAMI SNYDER TITLE: DIRECTOR PHONE: EMAIL: JAMI.SNYDER@AZAHCCCS.GOV	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,460,536
35	LOUISIANA DEPARTMENT OF HEALTH 628 N. 4TH STREET BATON ROUGE, LA 70802	ATTN: DR. COURTNEY N. PHILLIPS TITLE: SECRETARY PHONE: 225-287-2135 EMAIL: COURTNEY.PHILLIPS@LA.GOV	PAYOR REBATES	UNLIQUIDATED			\$ 1,407,395
36	TEXAS HEALTH AND HUMAN SERVICES COMMISSION NORTH AUSTIN COMPLEX 4601 W. GUADALUPE ST. AUSTIN, TX 78751	ATTN: CECILE ERWIN YOUNG TITLE: EXECUTIVE COMMISSIONER PHONE: 512-695-5057 EMAIL: CECILE.YOUNG@HHSC.STATE.TX.US	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,399,777
37	NJ ENCOUNTER MCO DRUG REBATE PROGRAM PO BOX 712 TRENTON, NJ 08625	ATTN: JENNIFER LANGER JACOBS TITLE: ASSISTANT COMMISSIONER PHONE: 609-588-2604 EMAIL: JENNIFER.JACOBS@DHS.NJ.GOV	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,355,191
38	INDIANA MEDICAID DRUG REBATES 950 N MERIDIAN ST SUITE 1150 INDIANAPOLIS, IN 46204	ATTN: DANIEL RUSYNIAK TITLE: SECRETARY PHONE: 248-524-9731 EMAIL: DANIEL.RUSYNIAK@FSSA.IN.GOV	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,344,156
39	ABON 140 LEGRAND AVE NORTHVALE, NJ 07647	ATTN: ROBERT B. FORD TITLE: CHIEF EXECUTIVE OFFICER PHONE: 469-330-0100 EMAIL: ROBERT.FORD@ABBOTT.COM	PROFIT SHARING / TRADE DEBT	UNLIQUIDATED			\$ 1,341,293
40	MD DHMH HERBERT R. O'CONOR STATE OFFICE BUILDING 201 W. PRESTON STREET BALTIMORE, MD 21201	ATTN: DENNIS R SCHRADER TITLE: SECRETARY PHONE: 410-961-3793 EMAIL: DENNIS.SCHRADER@MARYLAND.GOV	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,212,946



Top Unsecured Creditors

Name of creditor and complete mailing address, including zip code	Name, telephone number, and email address of creditor contact	Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts)	Indicate if claim is contingent, unliquidated, or disputed	Amount of unsecured claim		
				If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
				Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
41 ILLINOIS DEPARTMENT OF PUBLIC AID RECOVERY UNIT/DRP EEO/AA OFFICE 401 S. CLINTON STREET, 7TH FLOOR CHICAGO, IL 60607	ATTN: TYLER WHITE TITLE: DRUG REBATE UNIT MANAGER PHONE: 217-524-4508 EMAIL: TYLER.P.WHITE@ILLINOIS.GOV	PAYOR REBATES	UNLIQUIDATED			\$ 1,208,840
42 VEEVA SYSTEMS INC 4280 HACIENDA DRIVE PLEASANTON, CA 94588-2719	ATTN: PETER GASSNER TITLE: CHIEF EXECUTIVE OFFICER PHONE: 925-461-8415 EMAIL: PETER.GASSNER@GMAIL.COM	TRADE DEBT				\$ 1,170,644
43 CMS FEDERAL REBATES MCOS 7500 SECURITY BOULEVARD BALTIMORE, MD 21244	ATTN: KAREN JACKSON TITLE: CHIEF OPERATING OFFICER PHONE: 202-619-0630 EMAIL: KAREN.JACKSON@CMS.HHS.GOV	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,164,345
44 MISSOURI DIVISION MED SERVICES 912 WILDWOOD JEFFERSON CITY , MO 65102	ATTN: PAULA F. NICKELSON TITLE: ACTING DIRECTOR PHONE: 753-751-6001 EMAIL:	CUSTOMER BALANCES	UNLIQUIDATED			\$ 1,135,212
45 FHSC-SC DRUG REBATE PO BOX 60009 CHARLOTTE , SC 28260-0009	ATTN: ROBERT M. KERR TITLE: DIRECTOR PHONE: 803-898-2580 EMAIL: RKERR@SCDHHS.GOV	CUSTOMER BALANCES	UNLIQUIDATED			\$ 944,061
46 DHS MANAGED CARE REBATE 052 PO BOX 64837 ST. PAUL , MN 55164-0837	ATTN: SUSAN WINKELMANN TITLE: ASSISTANT DIRECTOR PHONE: 651-431-6500 EMAIL: SUSAN.WINKLEMANN@STATE.MN.US	PAYOR REBATES	UNLIQUIDATED			\$ 934,307
47 DEPT OF VA 810 VERMONT AVE., NW WASHINGTON, DC 20420	ATTN: DENIS MCDONOUGH TITLE: VA SECRETARY PHONE: 202-273-5400 EMAIL:	CUSTOMER BALANCES	UNLIQUIDATED			\$ 891,249
48 ASTRAZENECA LP 1800 CONCORD PIKE PO BOX 15437 WILMINGTON, DE 19850-5437	ATTN: ARADHANA SARIN TITLE: CHIEF FINANCIAL OFFICER PHONE: 800-456-3669 EMAIL: ARADHANA.SARIN@ASTRAZENECA.COM	PROFIT SHARING	UNLIQUIDATED			\$ 885,504
49 EXPRESS SCRIPTS ONE EXPRESS WAY SAINT LOUIS, MO 63121	ATTN: AMY BRICKER TITLE: PRESIDENT PHONE: 636-346-7911 EMAIL: ABRICKER@EXPRESS-SCRIPTS.COM	CUSTOMER BALANCES	UNLIQUIDATED			\$ 866,330
50 STATE OF MICHIGAN-DCH CAPITOL VIEW BUILDING 201 TOWNSEND STREET LANSING , MI 48913	ATTN: ELIZABETH HERTEL TITLE: DIRECTOR PHONE: 517-281-3574 EMAIL: ELIZABETH.HERTEL@MICHIGAN.GOV	CUSTOMER BALANCES	UNLIQUIDATED			\$ 855,441

Fill in this information to identify the case:

Debtor name	Endo International plc		
United States Bankruptcy Court for the:	Southern	District of	New York
(State)			
Case number (If known):			

Official Form 202

Declaration Under Penalty of Perjury for Non-Individual Debtors

12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

**WARNING – Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.**

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- ☐ *Schedule A/B: Assets-Real and Personal Property* (Official Form 206A/B)
- ☐ *Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- ☐ *Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- ☐ *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- ☐ *Schedule H: Codebtors* (Official Form 206H)
- ☐ *Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- ☐ *Amended Schedule* \_\_\_\_\_
- ☒ *Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 50 Largest Unsecured Claims and Are Not Insiders* (Official Form 204)
- ☒ Other document that requires a declaration Form 201A: Consolidated Corporate Ownership Statement and List of Equity Security Holders

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 08/16/2022  
MM/DD/YYYY

x /s/ Mark T. Bradley  
Signature of individual signing on behalf of debtor

Mark T. Bradley  
Printed Name

Chief Financial Officer  
Position or relationship to debtor